Preventing Cytomegalovirus Infection in High-Risk Bone Marrow Transplant Patients

Phase III BMT CTN 1703 trial of cyclophosphamide, tacrolimus, and mycophenolate mofetil for prevention of GVHD following alloSCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Expert-selected summary slides on graft-versus-host disease to help diagnose and manage your patients with GVHD, from Clinical Care Options (CCO).

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Released: February 8, 2022

On-demand Clinical Care Options (CCO) webcast: expert faculty discuss treatment options for B-cell lymphomas, including updates from ASH 2021

Julie M. Vose, MD, MBA
Program Director Brad S. Kahl, MD John P. Leonard, MD Physicians: maximum of 2.25 AMA PRA Category 1 Credits™ Released: February 7, 2022 Expired: February 6, 2023